1. Scrip
  2. >>Business
  3. >>Earnings

Gilead’s TIGIT Program Perks Up After Lung Cancer Letdown

Oncology, HIV Offer R&D Catalysts In 2024

 
• By Alaric DeArment

The drug maker announced early data for zimberelimab/domvanalimab in gastrointestinal cancers that it called encouraging, though an analyst was more skeptical due to limited interpretability.

• Source: Shutterstock

Gilead Sciences, Inc. got what it called encouraging news from its anti-PD-1/TIGIT program just before announcing its third quarter earnings as a Phase II study showed clinical activity for the immuno-oncology combination in upper gastrointestinal cancers. It also highlighted a number of oncology, inflammation and virology catalysts for 2024, including earlier-than-expected data for its long-acting HIV pre-exposure prophylaxis (PrEP) program.

Foster City, CA-based Gilead announced its third quarter earnings on 7 November, with overall revenues of $7.1bn that were flat...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Stock Watch: Vaccine Skepticism Confounds Commercial Prospects For Shingrix And Gardasil

 
• By Andy Smith

The US political environment and vaccine hesitancy by the general population have affected the sale of safe vaccines with clinical utility and no competition. The confusion and contradictions in the recent ACIP meeting are likely to stoke these pressures further.

Top 10 Drugs Q2 2025: Mounjaro Overtakes Ozempic

 
• By Eleanor Malone

Eli Lilly’s Mounjaro overtook rival GLP-1 agonist Ozempic from Novo Nordisk to become the second-highest selling drug globally in the second quarter of 2025, while overall GLP-1 drug sales continued to swell.

Stock Watch: Is First To Market Always Best?

 
• By Andy Smith

The first approved anti-PD-1 antibody to market eased ahead of later entrants by sales. But efficacy, tolerability and ease of administration are factors that count beyond first-mover advantage.

Norway’s Nykode Upbeat About Cancer Vaccines After Tough Year

 
• By Kevin Grogan

The firm is concentrating on its Keytruda combo for head and neck cancer after being abandoned by Roche and boardroom battles.

More from Business

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 
• By Alaric DeArment

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By Andy Smith

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.